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Objectives: To develop a method to enable the large-scale antimicrobial susceptibility screening of Orientia tsu-
tsugamushi clinical isolates, using one timepoint and one concentration of antibiotics to considerably speed up
the time to result.
Methods: Growth, harvesting, multiplicity of infection (moi) and the day to determine the MICs were optimized
using five O. tsutsugamushi reference strains [susceptible (Karp, Kato and Gilliam) and putatively resistant (AFC-3
and AFSC-4)], one clinical isolate (UT76) and one rodent isolate (TA763). Subsequently, the MICs of azithromycin,
chloramphenicol and doxycycline for these strains and 51 clinical isolates including AFSC-7 were determined. An
optimal concentration was calculated using the epidemiological cut-off value.
Results: The conditions for O. tsutsugamushi infection, growth and harvesting were determined to be an moi of
100:1 and trypsinization with the peak growth on day 10. The resulting MICs were in line with previously pub-
lished susceptibility data for all reference strains, except for Karp and AFSC-4, which showed azithromycin MICs
of 0.0156 and 0.0313 mg/L, compared with 0.0078 and 0.0156 mg/L, respectively, in previous reports. The MIC of
doxycycline for AFC-3 was 0.125 mg/L compared with .4 mg/L in earlier reports. The final single screening con-
centrations were identified as: azithromycin, 0.125 mg/L; chloramphenicol, 8 mg/L; and doxycycline, 1 mg/L.
Conclusions: This simplified procedure facilitates the simultaneous screening of 48 isolates for actively monitor-
ing potential resistance of this important fever pathogen, with an 8-fold throughput improvement over early
methods. The data do not support the existence of doxycycline- and chloramphenicol-resistant scrub typhus.
Introduction
Orientia tsutsugamushi is an obligate intracellular Gram-negative
bacterium, the causative agent of scrub typhus. The disease is a
leading cause of treatable fever in Asia and Northern Australia,
with high incidences reported in Thailand, Laos and India.1,2
Recent reports from further afield, especially in South America,
suggest that this is a far more global pathogen and a possible
cause of febrile illness beyond the textbook-described ‘tsutsuga-
mushi triangle’.3,4 Scrub typhus is also a major cause of CNS infec-
tion in Asia.5–7
Scrub typhus is regarded as treatable with doxycycline, azithro-
mycin and chloramphenicol.8 However, clinical and laboratory
evidence for doxycycline resistance in scrub typhus was described
in Chiangrai, Northern Thailand, in 1996.9 Given the large burden of
disease and the significant mortality associated with it, these
reports sparked significant concern in the region.10 With the pos-
sible emergence of resistant strains, treatment guidelines may
need to be reconsidered.
In 2014 the WHO released a report highlighting the significant
threat posed by antimicrobial resistance (AMR) and its consequen-
ces. It is estimated that 700 000 people die from drug-resistant
pathogens per year. These numbers are predicted to rise, with the
majority of resulting deaths likely to occur in low- and middle-in-
come countries.11,12 To tackle the global spread of resistance it is
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important to monitor AMR patterns for a multitude of pathogens.
Antibiotic susceptibility testing (AST) is conventionally conducted
on isolates using disc diffusion, and Etest and broth microdilution
to determine the MICs of antibiotics.13 The MIC is defined at the
lowest antibiotic concentration that completely inhibits the growth
of bacteria. However, for obligate intracellular bacteria, such as O.
tsutsugamushi, which require host cells for multiplication, such
conventional AST methods cannot be used. For intracellular patho-
gens, such as O. tsutsugamushi, growth in in vitro cell culture can
be monitored by methods such as plaque assay,14–20 immuno-
fluorescence assay (IFA)21 and flow cytometry.21–23 However,
these methods are time-consuming (16–19 days), labour inten-
sive and difficult to interpret.
Quantitative real-time PCR (qPCR) has been used for the early
diagnosis and monitoring of drug susceptibility patterns for O. tsu-
tsugamushi24,25 and other intracellular bacteria such as Rickettsia
spp. and Coxiella burnetii.26–29 However, these studies use a variety
of timepoints and multiplicity of infection (moi) ratios making
them time-consuming and laborious and not suitable for the rou-
tine screening of clinical isolates in endemic settings.
The purpose of this study was to develop a standardized simpli-
fied AST method using qPCR and a single antibiotic concentration
at a specific timepoint to screen O. tsutsugamushi clinical isolates
to facilitate large-scale AST.
Materials and methods
Standard methods for growth and quantification
Cell culture
The mouse fibroblast cell line (L929) was maintained in RPMI 1640 (Gibco,
Invitrogen, USA), supplemented with 10% FBS (Gibco, Invitrogen, USA) and
incubated at 35C in a humidified atmosphere with 5% CO2, as described
previously.30
Antibiotics
Azithromycin (analytical standard, Sigma–Aldrich, UK), chloramphenicol
(BioReagent, suitable for plant culture, Sigma–Aldrich, UK), doxycycline
hyclate (.98% purified by HPLC, Sigma–Aldrich, UK) and ofloxacin (fluoro-
quinolone antibiotic,99% purified by HPLC, Sigma–Aldrich, UK) were used
for this study.
O. tsutsugamushi reference strains
Eight susceptible or putatively resistant O. tsutsugamushi isolates were
used (Table 1). These included three strains regarded as antibiotic suscep-
tible: Karp, Kato and Gilliam (obtained from the Australian Rickettsial
Reference Laboratory, Geelong, Australia). UT76 was isolated from a pa-
tient in Udon Thani, Thailand.31 TA763 was isolated from a Rajah rat (Rattus
rajah) in Ubon Ratchathani, Thailand.32 The putatively doxycycline-resistant
strains AFC-3, AFSC-4 and AFSC-7 were kindly provided by the Naval
Medical Research Center (NMRC, Silver Springs, MD, USA) (Table 1).
Ethics statement
This study was approved by the Ethics Committee of the Faculty of Tropical
Medicine, Mahidol University, Thailand (approval number MUTM 2016-076-
02). All bacteria in this study were isolated from patients who provided writ-
ten informed consent (and parents or legal guardians of any children pro-
vided written informed consent on their behalf).
O. tsutsugamushi patient isolates
Fifty-one O. tsutsugamushi clinical isolates (Thailand, n"6; Lao PDR,
n"45) collected from two study sites [Lao-Oxford-Mahosot-Hospital-
Wellcome Trust Research Unit (LOMWRU), Vientiane, Lao PDR and
Chiangrai Clinical Research Unit (CCRU), Chiangrai, Thailand] were included.
These isolates were collected as a part of multiple fever aetiology stud-
ies.5,33,34 O. tsutsugamushi culture from EDTA blood and subsequent identi-
fication and storage was performed as described previously.30,35 The
infectivity titre, defined as the DNA-derived bacterial load of the inoculum,
was determined using qPCR before freezing (cut-off"108–109 copies/lL)
and before infection of cell lines.36
Preparation of O. tsutsugamushi inoculum
Prior to every experiment the frozen inoculate was thawed at 37C, trans-
ferred to a 1.5 mL tube and centrifuged at 18 000g for 5 min. Sucrose-phos-
phate-glutamate (SPG) freezing buffer was discarded and the bacteria
resuspended in fresh cell culture media and transferred to 2 mL safe-lock
microfuge tubes. The cells were lysed using a vortex mixer vigorously at
maximum speed for 1 min. Lysed infected cells were centrifuged at 50g for
3 min to separate host cell debris. The supernatant was transferred into a
fresh tube and used in the experiments.
Bacterial quantification by qPCR targeting the 47 kDa gene
DNA from infected cells was extracted using the HotShot technique as
described previously.30 The O. tsutsugamushi DNA copy number was meas-
ured using qPCR targeting the 47 kDa gene as previously described,30,36
using 1lL DNA templates. DNA bacterial load under antibiotic treatment
was compared with the load with no antibiotic treatment as a control.
Optimized bacterial growth and harvesting conditions
moi validation
To optimize the condition to determine the MIC, O. tsutsugamushi strains
were inoculated onto monolayers of L929 cells in 24-well plates. Pathogen
numbers (DNA copies) corresponded to an moi of 100:1 (Orientia DNA
1%106 copies per 1%104 of L929 cells) or 1000:1 (Orientia DNA 1%107 copies
per 1%104 of L929 cells). After incubation for 2 h, the inoculum was
removed and infected cells were washed twice with 1% PBS before adding
culture media. To identify the optimal moi, the growth curves from the two
mois were compared.
Cell harvesting method
Cell monolayers were harvested by trypsinization (Trypsin-EDTA, Gibco,
10%, UK) or scraping (cell scraper, Corning, USA). Infected cells were col-
lected every day throughout the 12 days. Pathogens were quantified by
qPCR as described above.
Growth kinetics of susceptible and resistant O.
tsutsugamushi strains
L929 cells were inoculated into 24-well plates and incubated at 35C over-
night. Cell monolayers were then infected with O. tsutsugamushi at a final
moi of 100:1. Infected cells were cultured for 12 days and harvested at
days 0, 3, 4, 5, 6, 7, 10, 11 and 12. Bacterial loads of each day’s harvest were
measured by qPCR.
Data generation and analysis
To ensure reproducibility of results, all experiments in this study were con-
ducted in three independent experiments and each experiment was con-
ducted in triplicate. The mean and standard deviation (SD) were calculated
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for individual three experiments. An F-test was used to compare variances
between the scraping and trypsinization methods and ANOVA was used to
compare bacterial growth at the generated MIC in different experiments
using STATA v14.2 (College Station, TX, USA). Bacterial copy numbers be-
tween days 7 and 10 were compared using Student’s t-test. To standardize
between experiments the relative growth with different antibiotics was nor-
malized by comparison with non-antibiotic controls. Data visualization and
statistical analysis was performed using GraphPad Prism 7.0 (GraphPad
Software, Inc., San Diego, CA, USA), unless otherwise stated. Results were
considered significantly different if P,0.05.
AST method
Antibiotics
Two-fold serial dilutions of azithromycin (range from 0.00005 to
0.0625 mg/L), chloramphenicol (range from 0.009 to 10 mg/L), doxycycline
(range from 0.0002 to 0.250 mg/L) and ofloxacin (range from 0.5 to 32 mg/
L) were used to include concentrations previously reported.37–39
AST
Infected cells were washed twice with 1% PBS before adding culture media
with or without antibiotics. Infected cells were incubated at 35C with 5%
CO2 for 10 days, prior to harvest. As the bacterial growth was determined
using DNA copy numbers, it is not possible to determine whether all DNA
was derived from live bacteria. We determined MICs of azithromycin, chlor-
amphenicol, doxycycline and ofloxacin as the concentrations that inhibit
.90% of bacterial growth. As the MIC90 was used to calculate the cut-off
for screening, any isolates that were able to grow more than 10% when
compared with non-antibiotic controls were suspected to be resistant and
investigated further with a series of antibiotic dilutions to confirm the MICs
and review clinical data for that isolate.
Determination of single screening concentration
As described by CLSI, ECOFFinder was used to determine epidemiological
cut-off (ECOFF) values.40 The ECOFF is determined from the log2 estimates
of the mean and SD using non-linear regression curve fitting of pooled cu-
mulative datasets from our study (https://clsi.org/education/microbiology/
ecoffinder/). An ECOFF of 99% means that 99 out of 100 bacterial isolates
are susceptible with the concentration used.40 The ECOFF approach was
selected to determine the screening concentration, as it is closest to the
conventional ‘eyeball’ method used for extracellular organisms.40,41 The
‘eyeball’ method is visual inspection of MIC distributions to determine cut-
offs.
Results
In order to develop a standardized screening method for O. tsutsuga-
mushi antimicrobial susceptibility, the conditions for a reproducible
Table 1. List of O. tsutsugamushi reference strains and in vitro antibiotic susceptibility reports used in the development of the standardized AST
method
Strain Country of isolation (year) Doxycycline Azithromycin Chloramphenicol Ofloxacin Reference(s)
Karp New Guinea (1943) S S S NA 47,48
Kato Japan (1952) S NA S R 39,48,49
Gilliam Burma (1944) S NA S NA 48,50
UT76 Thailand (2003) NA NA NA NA 31
TA763 Thailand (1963) NA NA NA NA 32
AFC-3 Thailand (1991) R NA S NA 9
AFSC-4 Thailand (1990) R S NA NA 37
AFSC-7 Thailand (1990) R NA NA NA 51
NA, antibiotic susceptibility reports not available; S, susceptible; R, resistant.
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Figure 1. Comparison of variation between replicates of O. tsutsugamushi strain Kato growth using different harvesting methods. (a) Scraping
method. (b) Trypsinization method.
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method with limited variation between experiments and isolates
were defined in the first step.
Development of standardized growth and harvesting
conditions
Variations between trypsinization and the scraping method were
observed between different experiments, with the SD of Orientia
DNA in the experiment being higher when using the scraper com-
pared with trypsinization at day 5 (1 001 275 copies/lL versus
316 190 copies/lL), day 6 (825 686 copies/lL versus 242 163 cop-
ies/lL), day 7 (786 957 copies/lL versus 12 590 copies/lL), day 10
(1 275 464 copies/lL versus 197 736 copies/lL), day 11 (1 520 186
copies/lL versus 197 736 copies/lL) and day 12 (1 440 961 copies/
lL versus 292 027 copies/lL) (Figure 1). However, none of these
pairs was significantly different (P.0.05).
The growth rates between mois of 1000:1 and 100:1 were simi-
lar over 12 days when comparing the growth curve slopes. The
slope was calculated from the difference in bacterial load between
days divided by the number of days (1000:1 slope"0.39 versus
100:1 slope"0.35) (Figure 2).
Seven known susceptible and putatively resistant strains
(Karp, Kato, Gilliam, UT76, AFC-3, AFSC-4 and TA763) were used
to identify growth peaks. Although there were differences in
doubling times between strains, two growth peaks were con-
sistently identified at day 7 and day 10 (Figure S1, available as
Supplementary data at JAC Online). Six of the seven (85.7%)
strains showed no significant differences in bacterial loads on
day 7 or day 10. However, bacterial loads on day 10 were signifi-
cantly higher than day 7 for the Kato strain and therefore day
10 was chosen as the single harvesting day (Table 2). In sum-
mary the optimum conditions used for further investigation
were as follows: O. tsutsugamushi inoculated onto monolayers
with an moi of 1:100 in 24-well plates and cell monolayers har-
vested by trypsinization at day 10.
Development of screening methodology
AST of susceptible/resistant strains
The optimized growth methods described above were used to de-
termine the MICs of multiple strains (Table 3). The results suggest
that the MICs of chloramphenicol for the Karp and AFSC-4 strains
are similar (2.5 mg/L) (Table 3). However, the MIC of azithromycin
was estimated to be 2-fold lower for Karp than for AFSC-4
(0.0156 mg/L versus 0.0313 mg/L) and the MIC of doxycycline for
Karp was 4-fold lower when compared with AFSC-4, which is con-
sistent with published data (Table 3 and Figure S2). The MICs of
these two strains and other strains were consistent across three in-
dependent experiments (Table 3 and Figure S3). Moreover, the MIC
determined of ofloxacin for seven strains of O. tsutsugamushi was
8 mg/L, which is the same MIC as in a published report of the Kato
strain (Table 3 and Figure S4). This suggests that the methodology
developed here gives similar results for MICs compared with pub-
lished methods.
Determination of single screening concentration
To determine a single screening concentration to be used for rou-
tine AST, the MICs of 59 Lao and Thai patient isolates were deter-
mined using the above methods. MICs were further analysed
using ECOFFinder analysis to identify the optimal single screening
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Figure 2. Comparison of different mois of O. tsutsugamushi strain Kato.
Bacterial infection using mois of 1000:1 (continuous line) and 100:1 (bro-
ken line) over 12 days with growth peaks at day 7 (moi"1000:1) and at
day 10 (moi"100:1). The plotted data points represent the mean and
SD of three independent experiments.
Table 2. Growth data for O. tsutsugamushi strains
Strain
Estimated doubling
time (h)
Log of bacterial load (95% CI)
Pday 7 day 10
Karp 15.05 5.193 (4.791–5.595) 5.142 (4.907–5.377) 0.6639
Kato 19.85 5.593 (5.363–5.824) 5.847 (5.732–5.961) 0.0134a
Gilliam 12.03 5.537 (4.999–6.077) 5.887 (5.775–5.999) 0.0524
AFC-3 9.50 6.363 (5.650–7.076) 6.182 (5.857–6.508) 0.3782
AFSC-4 10.53 6.221 (6.000–6.442) 6.227 (6.050–6.404) 0.9334
TA763 13.89 5.367 (5.160–5.897) 5.590 (4.876–6.303) 0.6629
UT76 14.42 5.444 (5.354–5.535) 5.935 (5.113–6.756) 0.1223
aStatistically significant (P,0.05).
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concentration. The modes of azithromycin, chloramphenicol and
doxycycline MICs were 0.0156 mg/L (18/59, 30.5%), 1.25 mg/L
(31/59, 52.5%) and 0.125 mg/L (24/59, 40.7%), respectively
(Figure 3). As all isolates fell within the normal distribution curve
calculated by ECOFFinder and no outliers were detected, all tested
isolates were considered susceptible to the three antibiotics
(Figure 3).
Using ECOFF99%, the corresponding susceptible cut-offs of
azithromycin, chloramphenicol and doxycycline were 0.125 mg/L,
8 mg/L and 1 mg/L, respectively.
Therefore, based on optimization and ECOFF, the final sim-
plified AST screening method proposed for O. tsutsugamushi is
as follows: inoculate with an moi of 100:1 in 24-well
plates; incubate with 0.125 mg/L, 8 mg/L and 1 mg/L azithro-
mycin, chloramphenicol and doxycycline, respectively; grow
for 10 days; harvest using trypsinization; and determine the
pathogen load by qPCR.
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Figure 3. Distribution of MIC values of azithromycin (a), chloramphenicol (b) and doxycycline (c). The dashed line represents the best-fit line of the
MIC distribution of susceptible bacterial strain observations calculated by the ECOFFinder.
Table 3. MICs of four antibiotics for O. tsutsugamushi reference strains
Strain
MIC (mg/L) this study/reference data
azithromycin doxycycline chloramphenicol ofloxacin
Kato 0.0039/NA 0.0313/NA 2.500/1.56052 8/839
Gilliam 0.0313/NA 0.1250/NA 1.250/0.78152 8/NA
AFC-3 0.0156/NA 0.1250/>49 1.250/NA 8/NA
TA763 0.0313/NA 0.0156/NA 0.156/NA 8/NA
UT76 0.0156/NA 0.0625/NA 1.250/NA 8/NA
Karp 0.0156/0.007837 0.0625/0.062537 2.500/1.56052 8/NA
AFSC-4 0.0313/0.015637 0.250/>0.25037 2.500/NA 8/NA
NA, no comparative data available in the literature.
Superscript numbers correspond to the references for these published
data.
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Discussion
This article describes the development of a novel AST screening
methodology for O. tsutsugamushi, a significant cause of morbidity
and mortality in rural Asia.4,5 Firstly, we optimized inoculation,
growth and harvesting conditions to establish a reproducible and
robust tool that can easily be implemented in multiple biosafety
level 3 (BSL-3) laboratories. A single timepoint and single concen-
tration for AST testing was identified to simplify procedures and
optimize workload, human capacity and consumable require-
ments. This method is a significant improvement over previously
described tools that also only used one timepoint but required a
number of antibiotic concentrations.28,29,42 O. tsutsugamushi
growth was quantified using qPCR, as this method is more specific,
sensitive and faster than flow cytometry, IFA and plaque assay.14–
23,26,37,43 In comparison with published data derived two decades
ago the MICs described here varied by 2-fold,37 likely because of
the different quantification method as well as the frequency of
passages of the O. tsutsugamushi stocks. However, the MIC of
ofloxacin, which is an ineffective antibiotic for this pathogen,44
shows the same value as derived in an earlier study.39
The AST methodology described here is able to determine the
susceptibility of O. tsutsugamushi to the three common antibiotics
used for scrub typhus therapy (azithromycin, chloramphenicol and
doxycycline) with one, rather than multiple, screening concentra-
tions and yielding results in 10 days. Owing to the complexity of
intracellular pathogen growth and BSL-3 requirements this
remains a relatively complex process. However, compared with
earlier methods that used up to 10 concentrations per antibiotic
per isolate, the reduction in consumables including culture plates,
cell culture reagents and hands-on time is by at least a factor of
eight. Additionally, the described method allows not only simpler
data collection but also allows higher-throughput testing. It is pos-
sible to screen 48 isolates at the same time for three antibiotics,
whereas only 6 isolates at a time could comfortably be tested with
previous protocols. Such high-throughput processing would allow
more widespread monitoring of this emerging pathogen at nation-
al or regional laboratories with BSL-3 facilities to inform treatment
guidelines in a timely fashion. Other intracellular pathogens, such
as Rickettsia typhi and C. burnetii, also represent major causes of
disease and the current method could be adapted for these
organisms.
The single screening concentration was determined using the
ECOFF, a previously published method for non-intracellular patho-
gens, such as Candida auris.45 This report is the first using this ap-
proach for intracellular organisms. The current study compared
Karp, a doxycycline-susceptible strain, with two apparently
doxycycline-resistant strains (AFSC-4 and AFC-3).9,37 The results
are in line with very recent data, which suggest that these strains
are not resistant to doxycycline,3 in contrast to the data published
for these strains 21 years ago.9,37 The data from the current study
show that the MICs of both putatively resistant strains are compar-
able with non-resistant isolates, even if the AFC-3 and AFSC-4 MICs
are slightly higher than the Karp strain. These differences over
21 years could have resulted from multiple bacterial passages
affecting the antimicrobial susceptibility of O. tsutsugamushi.
The differences in detection methods between previous studies
and our experiments may also have contributed to these differen-
ces in MICs.
Limitations of the study include that only isolates from Laos
and Thailand were used and that only MIC data were used to cal-
culate the ECOFF while fever clearance time, pharmacological and
genetic marker considerations were not included.40 Further, con-
ventionally, ECOFF calculation requires 100 isolates representing
multiple different laboratories.46 However, there are very few labo-
ratories in the world that perform O. tsutsugamushi culture from
buffy coat. The current requirement for culture at BSL-3 limits the
technique to a few specialized centres. With the growing under-
standing of the importance of this pathogen and the use of mod-
ern techniques, cultured isolates should become more available
and our method could help to characterize their antimicrobial sus-
ceptibility rapidly. One key limitation is that by using DNA as the
endpoint parameter for AST determination it is unclear whether
the DNA is from live or dead bacteria.
The simultaneous rise of AMR as a global public health problem
and the great expansion of the known distribution of scrub typhus
has informed the necessity of developing the described method-
ology. These data, and those of Kelly et al.,3 question the existence
of doxycycline- and chloramphenicol-resistant scrub typhus but
give additional support to the evidence that O. tsutsugamushi is in-
trinsically resistant to fluoroquinolones.39,44 However, the wide
genetic diversity of O. tsutsugamushi suggests the possibility of
geographical diversity in antimicrobial susceptibility patterns that
should be investigated. The simplified methodology could be used
to screen large isolate sets to quantify local O. tsutsugamushi sus-
ceptibility to key antibiotics and inform treatment guidelines.
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